1441670-89-8

Basic information

• Product Name: ledipasvir interMediate
• Synonyms: (6S)-6-[5-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]heptane-5-carboxylic acid 1,1-dimethylester;Ledipasvir INT 3;ledipasvir interMediate ,(6S)-6-[5-(7-BroMo-9,9-difluoro-9H-fluoren-2-yl)-1H-iMidazol-2-yl]-5-azaspiro[2.4]heptane-5-carboxylic acid 1,1-diMethylethyl ester;Ledipasvir intermediate N-3;4)(6S)-6-[5-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5- azaspiro[2.4]heptane-5-carboxylic acid 1,1-dimethylethyl ester;(6S)-6-[5-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]heptanes-5-carboxylic acid 1,1-dimethylethyl ester;(6s)-TERT-BUTYL-6(5(7-BROMO-9,9-DIFLUORO-9h-FLUOREN-2-YI)-1h-IMIDAZOL-2YI)-5-AZASPIRO(2.4)HEPTANE-5-CARBOXYLATE;(6S)-6- [5-(7-Bromo-9,9-difluoro-9H-fluoren-2-yl)-IH-imidazol-2-yll-5-azaspiro
• CAS NO: 1441670-89-8
• Molecular Formula: C27H26BrF2N3O2
• Molecular Weight: 542.4150464
• EINECS: 1592732-453-0
• Mol File: 1441670-89-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 681.1±55.0 °C(Predicted)
• Appearance: /
• Density: 1.53±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 11.13±0.10(Predicted)
• CAS DataBase Reference: ledipasvir interMediate(CAS DataBase Reference)
• NIST Chemistry Reference: ledipasvir interMediate(1441670-89-8)
• EPA Substance Registry System: ledipasvir interMediate(1441670-89-8)

Safety Data

• Hazardous Substances Data: 1441670-89-8(Hazardous Substances Data)

Usage

General Description

Ledipasvir intermediate is a chemical compound used in the production of ledipasvir, an oral medication used to treat chronic hepatitis C. The intermediate is a key component in the synthesis of ledipasvir, a direct-acting antiviral agent that targets the hepatitis C virus. It is part of the class of drugs known as hepatitis C virus NS5A inhibitors, which work by blocking the function of NS5A protein in the hepatitis C virus. Ledipasvir intermediate is a crucial building block in the manufacturing process of ledipasvir, contributing to the effectiveness of the medication in treating hepatitis C infection.

Upstream product

• 1129634-44-1 (6S)-5-[(tert-butoxy)carbonyl]-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 
• 83321-23-7 1,1-bis(iodomethyl)cyclopropane 
• 136476-38-5 cyclopropane-1,1-diylbis(methylene) dimethanesulfonate 
• 1454843-77-6 (±)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 1412903-77-5 (6S)-1,1-dibromo-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 1499193-61-1 (S)-6-(2-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl) 5-tert-butyl 5-azaspiro[2.4]heptane-5,6-dicarboxylate 
• 84348-38-9 (S)-1-(tert-butoxycarbonyl)-4-methylenepyrrolidine-2-carboxylic acid 
• 631-61-8 ammonium acetate 
• 1441673-92-2 (S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylate 

Downstream Products

• 1256388-51-8 methyl [(2S)-1-{(6S)-6-[5-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]-hept-3-yl]-1H-benzimidazol-6-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate 
• 1502654-87-6 (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)carbamicacid methyl ester D-tartrate salt 
• 1256388-50-7 (1-{6-[5-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-aza-spiro[2.4]heptane-5-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester 

Relevant articles and documents

Ledipasvir preparation method

The invention discloses a Ledipasvir preparation method. The Ledipasvir preparation method includes steps: (1) Ledipasvir intermediate product 1-LD-B preparation; (2) Ledipasvir intermediate product 2-LD-E preparation; (3) Ledipasvir intermediate product 3-LD-F preparation; (4) Ledipasvir intermediate product 4-LD-J preparation; (5) Ledipasvir intermediate product 5-LD-L preparation; (6) Ledipasvir-LD-Q preparation. The Ledipasvir preparation method has advantages of technical maturity and stability, product quality stability, safety and reliability in production process and suitableness for industrial production.

Hepatitis C virus inhibitor, medical composition and application thereof

The invention provides a hepatitis C virus inhibitor, a medical composition and application thereof. The hepatitis C virus inhibitor is a compound as shown in a formula (I), or salt, hydrate or a solvent compound accepted in crystal forms and pharmacy. The compound disclosed by the invention has better hepatitis C viral protein NS5A restraining activity, has better pharmacodynamics/pharmacokinetics properties, is good in applicability and high in safety, can be used for preparing medicines for treating hepatitis C virus infection, and has favorable market development prospects.

SOLID FORMS OF AN ANTIVIRAL COMPOUND

Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.